• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The ratio of intratumour to stromal infiltrating lymphocytes better predicts prognosis in breast cancer.

作者信息

Zhang Baoyi, Wang Xiang, Cheng Chao

机构信息

Department of Chemical and Biomolecular Engineering, Rice University, Houston, Texas, USA.

Quantitative and Computational Biology Program, Graduate School of Biomedical Sciences, Baylor College of Medicine, Houston, Texas, USA.

出版信息

Clin Transl Med. 2023 May;13(5):e1265. doi: 10.1002/ctm2.1265.

DOI:10.1002/ctm2.1265
PMID:37218084
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10203537/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd50/10203537/9591ac08348a/CTM2-13-e1265-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd50/10203537/0c764ebeefe8/CTM2-13-e1265-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd50/10203537/fa8c9748fcbf/CTM2-13-e1265-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd50/10203537/9591ac08348a/CTM2-13-e1265-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd50/10203537/0c764ebeefe8/CTM2-13-e1265-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd50/10203537/fa8c9748fcbf/CTM2-13-e1265-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd50/10203537/9591ac08348a/CTM2-13-e1265-g003.jpg

相似文献

1
The ratio of intratumour to stromal infiltrating lymphocytes better predicts prognosis in breast cancer.肿瘤内浸润淋巴细胞与基质浸润淋巴细胞的比例能更好地预测乳腺癌的预后。
Clin Transl Med. 2023 May;13(5):e1265. doi: 10.1002/ctm2.1265.
2
CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.CD8+ 淋巴细胞浸润是基底样乳腺癌的一个独立预后良好的指标。
Breast Cancer Res. 2012 Mar 15;14(2):R48. doi: 10.1186/bcr3148.
3
Tumor-Infiltrating Lymphocyte Volume Is a Better Predictor of Disease-Free Survival Than Stromal Tumor-Infiltrating Lymphocytes in Invasive Breast Carcinoma.肿瘤浸润淋巴细胞浸润量比浸润性乳腺癌间质中的肿瘤浸润淋巴细胞更能预测无病生存。
Am J Clin Pathol. 2019 Oct 7;152(5):656-665. doi: 10.1093/ajcp/aqz088.
4
Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.基质肿瘤浸润淋巴细胞的最佳阈值：其在接受曲妥珠单抗新辅助化疗的HER2阳性乳腺癌中的预测和预后价值
Breast Cancer Res Treat. 2015 Nov;154(2):239-49. doi: 10.1007/s10549-015-3617-7. Epub 2015 Oct 26.
5
ALDH1 and tumor infiltrating lymphocytes as predictors for neoadjuvant chemotherapy response in breast cancer.醛脱氢酶1和肿瘤浸润淋巴细胞作为乳腺癌新辅助化疗反应的预测指标
Pathol Res Pract. 2018 May;214(5):619-624. doi: 10.1016/j.prp.2018.04.006. Epub 2018 Apr 18.
6
Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer.基质 ColXα1 的表达与肿瘤浸润淋巴细胞相关，并可预测 ER 阳性/HER2 阳性乳腺癌的辅助治疗结果。
BMC Cancer. 2019 Nov 1;19(1):1036. doi: 10.1186/s12885-019-6134-y.
7
Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.肿瘤浸润淋巴细胞（TILs）相关基因组特征可预测乳腺癌的化疗反应。
Breast Cancer Res Treat. 2018 Jan;167(1):39-47. doi: 10.1007/s10549-017-4502-3. Epub 2017 Sep 13.
8
CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.CD3 +、CD4 +和CD8 +肿瘤浸润淋巴细胞（TILs）是乳腺浸润性导管癌生存预后良好的预测指标。
Indian J Med Res. 2014 Sep;140(3):361-9.
9
Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy.肿瘤浸润淋巴细胞可预测接受抗Her-2治疗的乳腺癌患者的预后。
Oncotarget. 2017 Jan 17;8(3):5219-5232. doi: 10.18632/oncotarget.14124.
10
Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.上皮-间质转化驱动因子短尾相关蛋白的表达及肿瘤浸润性CD8⁺和FOXP3⁺淋巴细胞状态在预测乳腺癌新辅助化疗治疗反应中的作用
Tumour Biol. 2017 Jun;39(6):1010428317710575. doi: 10.1177/1010428317710575.

引用本文的文献

1
Development and validation of a gradient boosting machine-based model for predicting tumor-infiltrating lymphocyte proportions in breast cancer.基于梯度提升机的乳腺癌肿瘤浸润淋巴细胞比例预测模型的开发与验证
Am J Transl Res. 2025 Jul 25;17(7):5586-5601. doi: 10.62347/PDEW5000. eCollection 2025.
2
Extratumoral Signs of Malignant Nonspiculate and Noncalcified Masses on Mammography: Are They Associated With Prognostic Factors in Breast Cancer?乳腺钼靶检查中恶性非毛刺状及非钙化肿块的瘤外征象：它们与乳腺癌的预后因素相关吗？
Breast J. 2025 Jun 24;2025:2793342. doi: 10.1155/tbj/2793342. eCollection 2025.
3
A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer.

本文引用的文献

1
Deep Learning-Based Mapping of Tumor Infiltrating Lymphocytes in Whole Slide Images of 23 Types of Cancer.基于深度学习的23种癌症全切片图像中肿瘤浸润淋巴细胞的图谱绘制
Front Oncol. 2022 Feb 16;11:806603. doi: 10.3389/fonc.2021.806603. eCollection 2021.
2
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.不同的肿瘤浸润淋巴细胞图谱与局限性非小细胞肺癌的临床结局相关。
Ann Oncol. 2022 Jan;33(1):42-56. doi: 10.1016/j.annonc.2021.09.021. Epub 2021 Oct 13.
3
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
一种用于预测乳腺癌新辅助化疗病理完全缓解的真实世界临床病理模型。
Front Oncol. 2024 Feb 14;14:1323226. doi: 10.3389/fonc.2024.1323226. eCollection 2024.
肿瘤浸润淋巴细胞作为乳腺癌生物标志物的探索之旅：在检查点抑制时代的临床应用。
Ann Oncol. 2021 Oct;32(10):1236-1244. doi: 10.1016/j.annonc.2021.07.007. Epub 2021 Jul 24.
4
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.化疗在乳腺癌中诱导动态免疫反应，影响治疗效果。
Nat Commun. 2020 Dec 2;11(1):6175. doi: 10.1038/s41467-020-19933-0.
5
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.肿瘤浸润淋巴细胞及其在皮肤黑色素瘤中的预后价值。
Front Immunol. 2020 Sep 10;11:2105. doi: 10.3389/fimmu.2020.02105. eCollection 2020.
6
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.浸润淋巴细胞与不同亚型乳腺癌患者预后的关系：新辅助化疗治疗 3771 例患者的汇总分析
Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.
7
Estrogen receptor quantitative measures and breast cancer survival.雌激素受体定量测量与乳腺癌生存。
Breast Cancer Res Treat. 2017 Dec;166(3):855-864. doi: 10.1007/s10549-017-4439-6. Epub 2017 Aug 19.
8
Clinical significance of tumor-infiltrating lymphocytes in breast cancer.乳腺癌肿瘤浸润淋巴细胞的临床意义。
J Immunother Cancer. 2016 Oct 18;4:59. doi: 10.1186/s40425-016-0165-6. eCollection 2016.
9
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.肿瘤浸润淋巴细胞在三阴性乳腺癌中具有预后价值，并可预测早期乳腺癌曲妥珠单抗获益：FinHER 试验结果。
Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.
10
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.γ干扰素和淋巴细胞可预防原发性肿瘤的发生并塑造肿瘤免疫原性。
Nature. 2001 Apr 26;410(6832):1107-11. doi: 10.1038/35074122.